Amgen Inc AMGN

Amgen Inc. es una empresa de biotecnología. La compañía descubre, desarrolla, fabrica y entrega varios productos terapéuticos para humanos. Opera en el segmento de terapéutica humana. Su cartera de productos comercializados incluye Neulasta (pegfilgrastim); agentes estimulantes de la eritropoyesis (ESAs), como Aranesp (darbepoetina alfa) y EPOGEN (epoetina alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), y otros productos comercializados, como KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) y Corlanor (ivabradina). Se enfoca en terapéutica humana para el tratamiento de enfermedades graves en las áreas de oncología/hematología, enfermedades cardiovasculares y neurociencia. Sus candidatos a productos en Fase III incluyen Erenumab para la migraña episódica, Aranesp para los síndromes mielodisplásicos, BLINCYTO para la leucemia linfoblástica aguda e IMLYGIC para el melanoma metastásico.

Con 2 acciones de AMGN (USD 806,82) habrías recibido USD 19,88 en dividendos en los últimos 12 meses.

• Zacks Investment Research 1 oct

  Amgen (AMGN) Stock Dips While Market Gains: Key Facts

  Amgen (AMGN) declined 3.38% in the latest trading session, underperforming the broader market. While the company's upcoming earnings are projected to show modest growth with EPS of $5.69 (+0.89% YoY) and revenue of $9.91 billion (+3.68% YoY), analyst estimates have slightly declined by 0.15% over the past month. The stock holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 18.38, trading at a discount to its industry average, though its PEG ratio of 3.04 exceeds the industry average of 1.91.

  

• The Motley Fool 1 oct

  Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

  Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space.

  

• Zacks Investment Research 1 oct

  Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win

  At the 2026 EASD conference in Milan, Eli Lilly and Novo Nordisk presented competing clinical data in the weight-loss drug market. Lilly's retatrutide showed 34.9% of patients lost at least 25% of body weight, while Novo countered with cardiovascular safety data for Ozempic. The GLP-1 market is expanding rapidly with over 27% of global adults eligible for these medications, attracting competition from Pfizer, Amgen, and Regeneron. Healthcare ETFs like OZEM, HRTS, and THNR offer diversified exposure to this growing sector.

  

• GlobeNewswire Inc. 30 sept

  Coronary Artery Disease Clinical Trial Space Intensifies with 20+ Companies in Active Development | DelveInsight

  The coronary artery disease treatment landscape is rapidly evolving with 20+ pharmaceutical companies actively developing 22+ pipeline drugs. Key players including Roche, Verve Therapeutics, Amgen, and others are advancing therapies targeting residual cardiovascular risk through novel mechanisms such as Factor XI inhibitors, gene therapy, and anti-inflammatory approaches. Recent clinical trial progress includes positive Phase IIa results for vortosiran and Phase II initiation of SRSD107, signaling growing momentum in addressing high-risk CAD patients beyond conventional treatments.

  

• GlobeNewswire Inc. 30 sept

  Homozygous Familial Hypercholesterolemia (HoFH) - 7MM Market, Epidemiology, and Forecast - 2036 | RNAi and Targeted Therapies Expand Uptake and Investment Opportunities

  The HoFH market is expected to expand through 2036, driven by improved genetic screening, earlier diagnosis, and adoption of targeted lipid-lowering therapies. With approximately 1,840 diagnosed prevalent cases in the 7MM in 2025, the market is shifting toward long-acting, receptor-independent therapies including RNA interference agents and ANGPTL3 inhibitors. Key unmet needs include limited treatment efficacy for patients with minimal LDL receptor function, delayed diagnosis, and high treatment burden.